Latest News

Immune therapy eliminates tumour cells in early triple negative breast cancer

Immune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to late breaking results from the KEYNOTE-522 trial presented at the ESMO Congress 2019 in Barcelona, Spain. Interim results from the study, which is the first phase III trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.

Source link




Related posts

Integrating Responses at the Intersection of Opioid Use Disorder and Infectious Disease Epidemics: Proceedings of a Workshop (2018)

Newsemia

#StressReduction 101: This is a reminder that we need to #calmdown! #health #Wel…

Newsemia

Our Pre-ICO is open – Limited Supply – Got some questions about #OpuLabs? …

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy